Ryan J. Sullivan
Expertise in
9
conditions

Dr. Ryan J. Sullivan

The General Hospital Corporation
Boston, MA
Expertise in
9
conditions
Specialties:Hematology | Oncology
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
OverviewInsuranceLocationsClinical Research

Overview

Ryan Sullivan is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Sullivan is highly rated in 9 conditions, according to our data. His top areas of expertise are Melanoma, Melanoma of the Eye, Uveal Melanoma, Colonoscopy, and Thyroidectomy. Dr. Sullivan is currently accepting new patients.

His clinical research consists of co-authoring 358 peer reviewed articles and participating in 29 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Newton-Wellesley Hospital
Massachusetts General Hospital
Cooley Dickinson Hospital Inc,the
Brigham And Women's Hospital
Wentworth-Douglass Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

THE GENERAL HOSPITAL CORPORATION
55 Fruit St, Boston, MA 02114
617-726-2000
Other Locations
THE GENERAL HOSPITAL CORPORATION
2014 Washington St, Newton, MA 02462
617-219-1200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 07, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Dabrafenib, Trametinib, Spartalizumab (PDR001)
Study Phase: Phase 3
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Procedure, Biological, Other, Drug
Study Drugs: Dabrafenib, Navitoclax, Trametinib
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2024
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors
Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors
Enrollment Status: Terminated
Publish Date: October 16, 2024
Intervention Type: Other, Drug
Study Drugs: Dabrafenib, Onalespib, Trametinib
Study Phase: Phase 1
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Tocilizumab
Study Phase: Phase 2
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Enrollment Status: Completed
Publish Date: September 04, 2024
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drug: BVD-523
Study Phase: Phase 2
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma
A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, Dabrafenib, Trametinib
Study Phase: Phase 2
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
Enrollment Status: Suspended
Publish Date: February 02, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment
A Phase 2, Open-label, Multi-Arm Trial to Evaluate the Efficacy and Safety of BDB001 in the Treatment of Subjects With Advanced Solid Tumors That Have Progressed on Anti-PD-1 or Anti-PD-L1 mAb Treatment
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)
An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Biological
Study Phase: Phase 1
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Genetic
Study Phase: Phase 1
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
Enrollment Status: Terminated
Publish Date: September 03, 2020
Intervention Type: Biological, Other
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 09, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 20, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Enrollment Status: Terminated
Publish Date: February 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 23 Less Clinical Trials

358 Total Publications

Overcoming Resistance Mechanisms to Melanoma Immunotherapy.
Overcoming Resistance Mechanisms to Melanoma Immunotherapy.
Journal: American journal of clinical dermatology
Published: November 05, 2024
Similar Doctors
Expertise in
29
conditions
Dr. Jeffrey W. Clark
Hematology | Oncology
Expertise in
29
conditions
Dr. Jeffrey W. Clark
Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Clark is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Clark is highly rated in 29 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Tissue Biopsy. Dr. Clark is currently accepting new patients.

Expertise in
47
conditions
Dr. David J. Kuter
Hematology | Oncology
Expertise in
47
conditions
Dr. David J. Kuter
Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
617-724-0287
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Kuter is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Kuter has been practicing medicine for over 47 years is highly rated in 47 conditions, according to our data. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Autoimmune Hemolytic Anemia, and Splenectomy. Dr. Kuter is currently accepting new patients.

Expertise in
13
conditions
Dr. Noopur S. Raje
Hematology | Oncology
Expertise in
13
conditions
Dr. Noopur S. Raje
Hematology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Noopur Raje is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Raje is highly rated in 13 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Vertebroplasty. Dr. Raje is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile